Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.37 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 2/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16077196 | 1.00 | KDM1A (0.37) | KDM1AKDM1BDGAT1BACE1PDK2 | |
| SCHEMBL16040881 | 0.79 | KDM1A (0.39) | KDM1AKDM1BDGAT1BACE1 | |
| SCHEMBL16077176 | 0.79 | KDM1A (0.39) | KDM1AKDM1BDGAT1BACE1 | |
| SCHEMBL16077173 | 0.79 | KDM1A (0.39) | KDM1AKDM1BDGAT1BACE1 | |
| SCHEMBL16077246 | 0.79 | KDM1A (0.42) | KDM1AKDM1BDGAT1BACE1PDK2 | |
| SCHEMBL18104112 | 0.79 | KDM1A (0.42) | KDM1AKDM1BDGAT1BACE1PDK2 | |
| SCHEMBL16026211 | 0.79 | KDM1A (0.39) | KDM1AKDM1BDGAT1BACE1 | |
| SCHEMBL16041966 | 0.77 | — | — | |
| SCHEMBL18707600 | 0.77 | — | — | |
| SCHEMBL16026289 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9611261-B2 | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use | AMGEN INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20160280695-A1 | PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2016-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280695-A1 | PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | BACE1, BACE2, APP | KDM1A 2098/4885KDM1B 2179/4885DGAT1 1594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.